Improvement in overall survival with carfilzomib, lenalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma
Association of combined patterns of tobacco and cannabis use in adolescence with psychotic experiences
3 reasons to join M3 India Market Research Panel
- Contribute to improvements in Healthcare by sharing your insights
- Earn rewards in your free time
- Secure: We never share your personal information without your permission
Over 4 million Doctors across 9 countries
trust M3 Group for their daily practice.
M3 India is a Joint Venture between M3 Inc. Japan and Health Care at Home India Pvt. Ltd.
By leveraging internet based technologies, this initiative will expand access to information and enhance communication in the Indian healthcare sector.